GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CERo Therapeutics Holdings CERO · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

-18.66%

Close of 5 Nov 2026, in USD

About CERo Therapeutics Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

CERo Therapeutics Holdings is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on OTC under the ticker CERO. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $19.9m. At that date it held total assets of $3.6m and shareholders' equity of −$5.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
6 Oct 2021
Head office
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Christopher EhrlichChairman of the Board, Chief Executive Officer, since 2021$998,748
  • Mr. Andrew AlbertChief Financial Officer$102,406
  • Dr. Kristen PierceChief Development Officer$119,777
  • Mr. Brian AtwoodDirector, since 2021$1.8m
  • Mr. Shami PatelDirector$115,050
  • Mr. Michael ByrnesIndependent Director$29,925
  • Ms. Kathleen LaporteIndependent Director$29,925
  • Dr. Lindsey RolfeIndependent Director$29,925

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Phoenix Biotech Acquisition Corp. has a clear focus on healthcare and healthcare-related industries in the US and Europe.
  • The company has a strategic IPO date of October 6, 2021, for potential business combinations.
  • CERo Therapeutics Holdings Inc. is positioned to target healthcare sectors with no current operational constraints.

Weaknesses

  • The company has zero full-time employees, indicating limited operational capacity.
  • Phoenix Biotech Acquisition Corp. has not identified any specific business combination target yet.
  • No revenue generation has occurred since the company's formation.

Opportunities

  • The healthcare industry in the US and Europe offers significant growth potential for new acquisitions.
  • CERo Therapeutics Holdings Inc. can leverage the IPO date to attract healthcare-focused business combinations.
  • The blank check company structure allows for flexibility in targeting healthcare-related businesses.

Threats

  • The lack of a defined business combination target poses a risk to timely operations.
  • No revenue generation creates financial uncertainty for the company.
  • The absence of full-time employees may hinder effective business combination execution.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.